Nottingham Advisors Inc. Cuts Stock Holdings in Danaher Corporation (NYSE:DHR)

Nottingham Advisors Inc. decreased its position in shares of Danaher Corporation (NYSE:DHR) by 35.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,057 shares of the conglomerate’s stock after selling 577 shares during the quarter. Nottingham Advisors Inc.’s holdings in Danaher were worth $217,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in DHR. GHP Investment Advisors Inc. lifted its position in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 99 shares during the period. Heck Capital Advisors LLC bought a new position in Danaher during the fourth quarter valued at approximately $27,000. Sierra Ocean LLC lifted its position in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 76 shares during the period. Smallwood Wealth Investment Management LLC bought a new position in Danaher during the first quarter valued at approximately $31,000. Finally, Hurley Capital LLC bought a new position in Danaher during the fourth quarter valued at approximately $34,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman directly owned 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares in the company, valued at approximately $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.20% of the company’s stock.

Danaher Stock Up 1.4%

Shares of DHR stock opened at $205.60 on Monday. The company has a market capitalization of $147.22 billion, a price-to-earnings ratio of 43.74, a PEG ratio of 2.86 and a beta of 0.77. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The company’s fifty day moving average price is $196.38 and its 200-day moving average price is $203.44. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.72 EPS. Sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, July 25th. Shareholders of record on Friday, June 27th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. Danaher’s dividend payout ratio is currently 27.23%.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Bank of America lowered their price objective on shares of Danaher from $265.00 to $230.00 in a research report on Monday, April 14th. Jefferies Financial Group lowered their price objective on shares of Danaher from $260.00 to $230.00 and set a “buy” rating on the stock in a research report on Tuesday, April 22nd. Citigroup reiterated a “buy” rating on shares of Danaher in a research report on Monday, April 7th. The Goldman Sachs Group decreased their price target on shares of Danaher from $260.00 to $240.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 23rd. Finally, Wells Fargo & Company decreased their price target on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 23rd. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.